Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04139577 · ClinicalTrials.gov registry record · Phase 1
FMT In High-Risk Acute GVHD After ALLO HCT
A Phase 1 study of Hematopoietic Cell Transplantation and Acute Graft-Versus-Host Disease (Gvhd) Grade, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04139577 is a Phase 1 study of Hematopoietic Cell Transplantation and Acute Graft-Versus-Host Disease (Gvhd) Grade that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants, below the 237-participant average among 4 other Hematopoietic Cell Transplantation trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04139577, a Phase 1 study of Hematopoietic Cell Transplantation and Acute Graft-Versus-Host Disease (Gvhd) Grade, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) treatment in high-risk acute graft-versus-host disease (GVHD). This research study involves an experimental intervention called FMT.
Conditions Studied
Interventions
- BIOLOGICAL Fecal Microbiota Transplant
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2023-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04139577
The ClinicalTrials.gov registry entry for NCT04139577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 4 other Hematopoietic Cell Transplantation trials with a reported enrollment target (96% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hematopoietic Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Fecal Microbiota Transplant is the first listed.
NCT04139577 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04139577 about?
NCT04139577 is a clinical study titled "FMT In High-Risk Acute GVHD After ALLO HCT". The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) treatment in high-risk acute graft-versus-host disease (GVHD). This research study involves an experimental intervention called FMT.
What is the current status of trial NCT04139577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-06-18. Estimated completion is 2023-01-05.
What conditions does trial NCT04139577 study?
This clinical trial studies the following conditions: Hematopoietic Cell Transplantation, Acute Graft-Versus-Host Disease (Gvhd) Grade, Fecal Microbiota Transplant.
What interventions are being tested in trial NCT04139577?
The interventions under investigation include: Fecal Microbiota Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT04139577?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04139577 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
RECRUITING · Phase 1
-
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
RECRUITING
-
A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
RECRUITING
-
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Hematopoietic Cell Transplantation
All registered trials for this condition
Acute Graft-Versus-Host Disease (Gvhd) Grade
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.